When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Raynaud phenomenon

Última revisión: 15 Aug 2025
Última actualización: 04 Oct 2024

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • digit pain/discomfort
  • digital paresthesia
  • pallor of digits
  • red and/or blue discoloration of digits
  • dilated capillaries at nailbeds
  • well-defined discoloration
  • magnification of nailbeds
Todos los datos

Otros factores de diagnóstico

  • heartburn
  • dysphagia
  • puffy hands
  • tight skin
  • arthralgia
  • photosensitivity
  • oral/nasal ulcers
  • alopecia
  • butterfly rash
  • sclerodactyly
  • telangiectasia
  • pleuritic chest pain
  • digital ulcers
  • digital pits
  • digital tuft resorption
  • gangrene of fingertip/finger
  • raised painful red lesions on finger tips
  • autoamputation
Todos los datos

Factores de riesgo

  • female
  • family history
  • connective tissue disease
  • use of certain drugs
  • vibration injury
  • Buerger disease
  • prolonged cold exposure/frostbite
  • colder climate
  • smoking
  • ischemia
  • migraine
  • glaucoma
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • clinical diagnosis
  • antinuclear antibody
  • CBC
  • erythrocyte sedimentation rate
  • C-reactive protein
  • urinalysis
Todos los datos

Pruebas diagnósticas que deben considerarse

  • capillaroscopy
Todos los datos

Algoritmo de tratamiento

Agudo

severe secondary RP: critical ischemia with digital ulcers or threatened digital loss

En curso

primary or mild secondary RP

Colaboradores

Autores

Janet Pope, MD, MPH, FRCPC
Janet Pope

Professor of Medicine

Division of Rheumatology

Department of Medicine

University of Western Ontario

Schulich School of Medicine and Dentistry

Head

Division of Rheumatology

St. Joseph's Health Care

London

Ontario

Canada

Divulgaciones

JP has been reimbursed for consulting with several pharmaceutical manufacturers unrelated to Rayaud phenomenon. JP’s institution receives research grants from BMS, Janssen, and Seattle Genetics. She has acted as a consultant for AbbVie, Amgen, AstraZeneca, BI, BMS, Celltrion, EMERALD, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Organon, Pfizer, Sandoz, Samsung, and Viatris. JP is a speaker and advisory board member for AbbVie, Amgen, AstraZeneca, BI, BMS, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Novartis, Organon, Pfizer, Sandoz, UCB, and Viatris. She receives no patents or royalties. JP is an author of a number of references cited in this topic.

Revisores por pares

Elena Schiopu, MD

Professor of Medicine

Rheumatologist

Medical College of Georgia at Augusta University

Charlie Norwood Veterans Affairs Medical Center

Augusta

GA

Divulgaciones

ES declares that she has no competing interests.

Ariane L. Herrick, MD FRCP

Reader in Rheumatology and Consultant Rheumatologist

Musculoskeletal Research Group

University of Manchester

Manchester

UK

Divulgaciones

ALH has been a paid speaker for Actelion; a consultant for Actelion and Pfizer; and an investigator in studies sponsored by Actelion, Mediquest, and United Therapeutics. ALH is an author of a number of references cited in this topic.

Bridget Griffiths, MB ChB, MD, MRCP(UK)

Consultant Rheumatologist

Department of Rheumatology

Freeman Hospital

Newcastle upon Tyne

UK

Divulgaciones

BG declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Curtiss P, Svigos K, Schwager Z, et al. Part I: epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol. 2024 Feb;90(2):223-34. Resumen

Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23.Texto completo  Resumen

Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Raynaud phenomenon images
  • Diferenciales

    • Normal response to cold
    • Cyanosis/cryoglobulinemia
    • Chilblains (perniosis)
    Más Diferenciales
  • Guías de práctica clínica

    • The 2024 British Society for Rheumatology guideline for management of systemic sclerosis
    • EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
    Más Guías de práctica clínica
  • Folletos para el paciente

    Quitting smoking

    Raynaud phenomenon

    Mais Folletos para el paciente
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal